Sanofi has decided to stop the clinical development of amlitélimab, an antibody for moderate to severe atopic dermatitis, after strategic review showed insufficient efficacy and safety benefits. Despite some positive long-term results from the phase 3 ESTUARY study, amlitélimab does not significantly improve current standard treatments. Sanofi will close ongoing studies carefully and continue pursuing advances in inflammatory skin disease treatments. Financial forecasts for 2026 remain unchanged.
Sanofi has decided to stop the clinical development of amlitelimab, a monoclonal antibody for moderate-to-severe atopic dermatitis (AD), after reviewing its efficacy and safety data. Despite positive long-term results from the ESTUARY phase 3 study, ...
Scribe Therapeutics, a clinical-stage biotech company focused on CRISPR-based genetic therapies, priced its upsized initial public offering at $15 per share, raising approximately $128.7 million before expenses. The shares will begin trading on Nasda...
Sanofi announced changes to its Executive Committee effective September 1, 2026, aligning leadership across key business areas to support its upcoming strategic priorities. New roles include expanded responsibilities for Finance and Vaccines, with le...
